Lots of interesting abstracts and cases were submitted for TCTAP 2025. Below are the accepted ones after a thorough review by our official reviewers. Don’t miss the opportunity to expand your knowledge and interact with authors as well as virtual participants by sharing your opinion in the comment section!
TCTAP A-025
Efficacy and Safety of Drug-Coated Balloon for Treatment of De Novo Left Anterior Descending Artery and Left Circumflex Artery Ostial Lesions
By Haoyu Wu, Haichao Chen
Presenter
Haoyu Wu
Authors
Haoyu Wu1, Haichao Chen1
Affiliation
Shaanxi Provincial People’s Hospital, China1
View Study Report
TCTAP A-025
Bifurcation
Efficacy and Safety of Drug-Coated Balloon for Treatment of De Novo Left Anterior Descending Artery and Left Circumflex Artery Ostial Lesions
Haoyu Wu1, Haichao Chen1
Shaanxi Provincial People’s Hospital, China1
Background
The optimal interventional treatment approach for left anterior descending artery (LAD) and left circumflex artery (LCX) ostial lesions is controversial. There is limited evidence on the use of drug-coated balloon (DCB) for the treatment of de novo ostial lesions of LAD and LCX. This study aimed to explore the efficacy and safety of DCB strategy in patients with LAD or LCX ostial lesions compared with drug-eluting stents (DES) strategy.
Methods
Patients with de novo ostial lesions in LAD or LCX who underwent percutaneous coronary intervention using only DCB (DCB group) or only DES (DES group) were enrolled. The DCB group used a crossover technique. The DES group used a crossover or precise stenting technique. One-year major adverse cardiovascular events (including cardiovascular death, target vessel myocardial infarction, or ischemia-driven target lesion revascularization) were evaluated.
Results
A total of 158 patients with de novo ostial lesions in LAD or LCX were enrolled. Of the participants, 56 were treated with only DCB (DCB group) and 102 with only DES (DES group) strategy. During one-year follow-up, there was no significant difference in the incidence of major adverse cardiovascular events between the DCB group and the DES group (14.3% vs. 17.6%, P = 0.57).
Conclusion
The use of DCB approach to treat patients with de novo LAD and LCX ostial lesions is effective and safe. DCB can be considered a safe option for de novo LAD or LCX ostial lesions.